clinical trial · NCT07458113
Sac-TMT for Active TNBC Brain Metastases
Yale University·phase2·not yet recruiting·n = 20
Metastatic Triple Negative Breast CancersSacituzumab tirumotecan
brief summary
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, consent withdrawal, or death.
started
May 1, 2026
primary completion
May 1, 2028
completion
May 1, 2029
last updated
Mar 9, 2026
official title
Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol